COMMUNIQUÉS West-GlobeNewswire

SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival
02/09/2025
Study shows approximately 18% savings per hospitalization DENVER, Sept. 02, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming [...]
First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter
02/09/2025
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful completion of the [...]
STRATA Skin Sciences IP Portfolio Holds Exclusivity in Combination Therapies of Its XTRAC Excimer Laser with JAK Inhibitors, Systemic and Biologic Drugs, Bolstering Expansion into New Indications Like Vitiligo and Other Auto-Immune Skin Conditions
02/09/2025
Strata continues to work closely with CMS to ensure a rapid implementation of the extended codes HORSHAM, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a [...]
IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
02/09/2025
LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a pre-recorded [...]
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
02/09/2025
NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
02/09/2025
BERKELEY, Calif. and MAINZ, Germany, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of [...]
Nkarta to Participate in a September Investor Conference
02/09/2025
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its [...]
Coag-Sense® PT/INR Monitoring System Approved for Patient Self-Testing in Europe
02/09/2025
FREMONT, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- CoaguSense, Inc., a subsidiary of i-SENS (KOSDAQ:099190), today announced that it has received approval for the sale of the Coag-Sense ® PT/INR Monitoring System for [...]
Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
02/09/2025
SAN DIEGO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with [...]
Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
02/09/2025
PITTSBURGH, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Cantor Global Healthcare Conference 2025 on September 4, 2025 [...]
Step Pharma announces first participant dosed in a phase 1b clinical trial of dencatistat for essential thrombocythaemia
02/09/2025
Start of the phase 1b trial in a new indication expands Step Pharma’s clinical programme, building on the development of dencatistat in lymphoma and solid tumours This milestone marks the third indication for [...]
OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease
02/09/2025
Collaboration leverages OMass’ Odyssion TM platform for the continued development of oral small molecules against a first-in-class target in inflammatory bowel disease OMass to receive $20 million upfront payment, with [...]
PETVIVO HOLDING, INC. ANNOUNCES DISTRIBUTION AGREEMENT WITH NUPSALA LIMITED
02/09/2025
MINNEAPOLIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., a wholly-owned subsidiary of PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) ( collectively referred to herein as "PetVivo"), is an [...]
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
02/09/2025
NORCROSS, Ga., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will [...]
REMINDER – Biocodex Microbiota Foundation invites Canadian academics and scientists to apply for €35,000 research grant
02/09/2025
The objective is to advance microbiota’s role study in human health & diseases MONTREAL, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation , an organization founded by Biocodex and dedicated to [...]
RAPPEL – La Fondation du Microbiote de Biocodex invite les universitaires et scientifiques canadiens à soumettre leur candidature pour une bourse de recherche de 35 000 €
02/09/2025
L’objectif est de faire progresser l’étude du rôle du microbiote sur la santé et les maladies humaines MONTRÉAL, 02 sept. 2025 (GLOBE NEWSWIRE) -- La Fondation du Microbiote de Biocodex , une organisation fondée par [...]
Highridge Medical Acquires Innovative Products from Accelus to Expand Capabilities in Spine Surgery
02/09/2025
Deal adds innovative expandable cage and other implant technology to the Highridge portfolio. WESTMINSTER, Colo., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Highridge Medical, one of the world’s largest privately held spine [...]
Stereotaxis to Present at Upcoming Investor Conferences
02/09/2025
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fischel, Chairman and [...]
Emergent BioSolutions Awarded $30 Million Contract Modification for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted), a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
02/09/2025
GAITHERSBURG, Md., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $30 million contract modification from the Biomedical Advanced Research and Development [...]

Pages